DPP抑制剂从指南到临床.pptVIP

* Sitagliptin vs Metformin in Type 2 Diabetes Mellitus: Sitagliptin Is Noninferior to Metformin Reductions in HbA1c at week 24 were observed in both the sitagliptin and metformin treatment groups (0.43% and 0.55%, respectively).1 Although metformin demonstrated numerically greater reductions in HbA1c at 24 weeks, there was no significant difference between treatment groups for change from baseline in HbA1c in the per-protocol population (between-groups difference=0.14%; 95% confidence interval [0.06, 0.21]).1 These results indicated that sitagliptin was noninferior to metformin for the primary efficacy end point (prespecified noninferiority margin=0.40%). The primary per-protocol analysis is supported by an analysis based on the full analysis set population.1 PurposeTo show the HbA1c-lowering efficacy of sitagliptin vs that of metformin after 24 weeks of treatment. TakeawayReductions in HbA1c at week 24 were similar for both treatment groups. 1. Aschner P et al. Diabetes Obes Metab. 2010;12(3):252–261. * Sitagliptin in Older Patients With Type 2 Diabetes: Study Design This was a 24-week, multicenter, randomized, double-blind, parallel-group study of patients ≥65 years with type 2 diabetes.1 The objective of this study was to assess the efficacy and safety of sitagliptin monotherapy over 24 weeks in elderly patients (≥65 years of age) with type 2 diabetes who had inadequate glycemic control. This study enrolled 206 patients with type 2 diabetes who had inadequate glycemic control (HbA1c 7%–10%).1 Patients not taking an oral antihyperglycemic agent (OHA) for ≥8 weeks with a baseline HbA1c of ≥7% and ≤10% were eligible to directly enter a 2-week, single-blind placebo period. Patients not taking an OHA for ≥8 weeks with a baseline HbA1c 10% were given 6 weeks to achieve an HbA1c of ≥7% and ≤10% with diet and exercise counseling before they could enter the 2-week, single-blind placebo period.1 Patients receiving OHA monotherapy or low-dose combination the